Particularly, loss of IGFBP2 is associated with resistance to anti-IGF1R treatment due to hyperactivation of IGF signaling in rhabdomyosarcoma [85], while overexpression of IGFBP2 drives dasatinib resistance through activation of FAK in non-small cell lung cancer cells [86]. The gene discussed is IGF1R; the disease is rhabdomyosarcoma.